ERIS Lifescience
ERIS Lifescience Q2 Results 2026 (FY27): Revenue ₹892 Cr, PAT ₹187 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
ERIS Lifescience Q2 FY27 key numbers
- Revenue
- Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth.
As stated in ERIS Lifescience's Q2 FY27 investor presentation · published 26 Oct 2026. Reported figures, not investment advice.
Based on ERIS Lifescience's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth (Page 13,14) - Domestic Branded Formulations (DBF) Q2 FY27 Revenue: ₹809 crore, a 14.1% YoY growth (Page 9) - DBF Q2 FY27 ex-Zorvia growth: 16.5% YoY (Page 5) - International Business Q2 FY27 revenue was flat vs. Q2 FY27 EBITDA: ₹309 crore, up 7.3% YoY; EBITDA margin: 34.7% (compared to 36.4% in Q2 FY26) (Page 14-15) - Q2 FY27 Profit After Tax (PAT): ₹187 crore, up 39.2% YoY; PAT margin: 21.0% (Page 14-15) - A
From ERIS Lifescience's Q2 FY27 earnings-call transcript · updated 26 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth (Page 13,14)
- Domestic Branded Formulations (DBF) Q2 FY27 Revenue: ₹809 crore, a 14.1% YoY growth (Page 9)
- DBF Q2 FY27 ex-Zorvia growth: 16.5% YoY (Page 5)
- International Business Q2 FY27 revenue was flat vs. Q2 FY26 at ₹83 crore (Page 11)
- Diabetes therapy contributed 9.5% to the portfolio with a 37.3% growth in Q2 (Page 8)
- No explicit numeric outlook for future revenue or volumes is stated. However, the presentation mentions:
- "Levers for further ROCE Improvement" and expected returns from major capital investments starting next year (Page 14)
2 more points from ERIS Lifescience's call on revenue
Create a free account to keep reading this call
Profitability & Margins
- Q2 FY27 EBITDA: ₹309 crore, up 7.3% YoY; EBITDA margin: 34.7% (compared to 36.4% in Q2 FY26) (Page 14-15)
- Q2 FY27 Profit After Tax (PAT): ₹187 crore, up 39.2% YoY; PAT margin: 21.0% (Page 14-15)
- Adjusted PAT for Q2 FY27: ₹158 crore, up 17.5% YoY; Adjusted PAT margin: 17.7% (Page 14-15)
- Domestic Branded Formulations (DBF) Q2 FY27 EBITDA: ₹288 crore, up 8.3% YoY; EBITDA margin: 35.7% (down 191 bps YoY) (Pages 5, 9)
- DBF PAT Q2 FY27: ₹170 crore, up 42.7% YoY; PAT margin: 21.1% (Page 9)
2 more points from ERIS Lifescience's call on margins
Create a free account to keep reading this call
Capital Expenditure Plans
2 more points from ERIS Lifescience's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Order Book & Pipeline
See what ERIS Lifescience said on order book & pipeline — free account, 30 seconds.
ERIS Lifescience — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹892 Cr, net profit ₹187 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Venus Remedies Ltd (Q2 FY27)
219.27 crores compared to Rs. Key results statement takeaways from Venus Remedies Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sat Kartar Life Ltd (Q2 FY27)
This represents a year-on-year revenue increase of approximately 26.43% [(11,387.49 . Key investor presentation takeaways from Sat Kartar Life Ltd's Q2 FY27 inv
- Sakar Healthcare Ltd (Q2 FY27)
Q2 FY27 revenue from operations: INR 8,741.61 Lakhs, up 52% YoY from INR 5,756.04 Lakhs in Q2 FY26 (Page 7). Key investor presentation takeaways from Sakar Heal
- Dr Reddys Laboratories Ltd (Q2 FY27)
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre
Arthneeti Pro · Annual
ERIS Lifescience and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were ERIS Lifescience Q2 FY27 results?
Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth (Page 13,14) - Domestic Branded Formulations (DBF) Q2 FY27 Revenue: ₹809 crore, a 14.1% YoY growth (Page 9) - DBF Q2 FY27 ex-Zorvia growth: 16.5% YoY (Page 5) - International Business Q2 FY27 revenue was flat vs. Q2 FY27 EBITDA: ₹309 crore, up 7.3% YoY; EBITDA margin: 34.7% (compared to 36.4% in Q2 FY26) (Page 14-15) - Q2 FY27 Profit After Tax (PAT): ₹187 crore, up 39.2% YoY; PAT margin: 21.0% (Page 14-15) - A
What is ERIS Lifescience share price analysis?
ERIS Lifescience currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹15,199 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifescience planning capital expenditure?
Capex cycle expected to wind down by end of FY27 (Page 14).
Keep ERIS Lifescience on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.